ESMO2023: Phase I open-label, dose escalation and expansion study of YH003 in combination with Toripalimab in patients with advanced solid tumors
Conclusions
YH003 was well tolerated up to 1.0 mg/kg dose levels when combined with Toripalimab. Based on the safety, efficacy and PK data of YH003002, the RP2D of YH003 for part 2 expansion stage was 0.3 mg/kg. The combination of YH003 and Toripalimab has shown encouraging antitumor activity in patients with advanced solid tumors.
